ALAMEDA, Calif., Dec. 5, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN) a biopharmaceutical company innovating therapeutics for neurological care, announced today that Avigen will present information on the company's development programs and product pipeline at two upcoming healthcare conferences:
* Wednesday, December 12, 2007 -- RBC Capital Markets Healthcare
Conference 9:00-10:00 a.m. EST in New York City at the Westin
Times Square Hotel
Avigen's Chief Business Officer, Michael Coffee, will
participate in a panel on new approaches to pain treatment.
Mr. Coffee's presentation will be webcast live and archived on
Avigen's website at www.avigen.com.
* Wednesday, December 12, 2007 -- Windhover's Bio/Pharma
Partnerships Conference 4:25-4:45 p.m. PST in San Francisco at
the Fairmont Hotel
Avigen's Vice President of Finance, Andrew Sauter, will present.
About Avigen
Avigen is a biopharmaceutical company focused on unique small molecule therapeutics and biologics to treat serious neurological disorders, including neuropathic pain and neuromuscular spasm and spasticity. Avigen's strategy is to complete the requirements of clinical development for each of the candidates in its product pipeline, and continue to look for opportunities to expand its pipeline through a combination of internal research, acquisitions, and in-licensing, with the goal of becoming a fully integrated commercial biopharmaceutical company committed to its small molecule and biologics neurology products. The company currently has in development AV650 for neuromuscular spasm and spasticity and AV411 for neuropathic pain. Additionally, the company has in development AV513, a compound for the treatment of hemophilia A and B. For more information about Avigen, consult the company's website at www.avigen.com.
The Avigen, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=2981
Statement under the Private Securities Litigation Reform Act
This press release contains forward-looking statements, which include, among others, statements relating to Avigen's intention of completing the requirements of clinical development for each of the candidates in its product pipeline, looking for opportunities to expand its pipeline through a combination of internal research, acquisitions, and in-licensing; and becoming a fully integrated commercial biopharmaceutical company. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include those detailed in reports filed by Avigen with the Securities and Exchange Commission, including Avigen's Quarterly Report on Form 10-Q for the period ended September 30, 2007, under the caption "Risks Related to our Business" in Item 2 of Part I of that report, which was filed with the SEC on November 8, 2007.